Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 71335-1908

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 71335-1908). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351908)

Label for Memantine Hydrochloride 10 mg film-coated tablets by Bryant Ranch Prepack. The label states the product is a gray capsule shaped 322, packaged quantity of 30 tablets, with an NDC of 71335-1908-1. It includes storage instructions to keep at room temperature (20°-25°C) and to keep out of reach of children. The label references a comparison to Namenda 10 mg tablets by Sun Pharma Industries Ltd.*

FDA Label Image

Spl-memantine-chemical-structure (Spl Memantine Chemical Structure)

Chemical structure of Memantine Hydrochloride, showing a tricyclic amine framework with two methyl groups and an amine group attached, along with the hydrochloride component indicated.*

FDA Label Image

Spl-memantine-figure1 (Spl Memantine Figure1)

A line graph showing the mean change from baseline in ADCS-ADL scores over 28 weeks of treatment. Two groups are plotted: placebo and memantine hydrochloride. The memantine group shows less decline over time compared to placebo, with clinical improvement and decline indicated on the graph. Error bars represent standard error of the mean (SEM).*

FDA Label Image

Spl-memantine-figure2 (Spl Memantine Figure2)

A cumulative percentage line graph comparing patients treated with Memantine Hydrochloride and placebo over 28 weeks. The x-axis shows ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients. The graph illustrates patient response differences between the two groups.*

FDA Label Image

Spl-memantine-figure3 (Spl Memantine Figure3)

A line graph illustrating the time course of change from baseline in SIB score over 28 weeks of treatment, comparing Memantine Hydrochloride and placebo. The y-axis shows the mean (± SEM) change, with annotations for clinical improvement and clinical decline, while the x-axis indicates weeks of treatment. Data points for Memantine Hydrochloride and placebo are shown with distinct markers and error bars.*

FDA Label Image

Spl-memantine-figure4 (Spl Memantine Figure4)

A cumulative percentage graph showing patient outcomes over 28 weeks of double-blind treatment comparing Memantine Hydrochloride to placebo. The x-axis represents SIB change from baseline, while the y-axis shows the cumulative percentage of patients. Two curves depict higher patient percentages achieving SIB score changes with Memantine Hydrochloride versus placebo.*

FDA Label Image

Spl-memantine-figure5 (Spl Memantine Figure5)

A line graph depicting the mean change from baseline in ADCS-ADL score over 24 weeks of treatment. It compares Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups, showing clinical improvement and decline on the y-axis and weeks of treatment on the x-axis. The graph includes error bars and a legend for each treatment group.*

FDA Label Image

Spl-memantine-figure6 (Spl Memantine Figure6)

A cumulative percentage curve chart comparing patients treated with Memantine Hydrochloride/Donepezil versus Placebo/Donepezil over 24 weeks. The x-axis represents the change from baseline in ADCS-ADL scores, while the y-axis shows the cumulative percentage of patients. The chart illustrates differences in treatment response between the two groups.*

FDA Label Image

Spl-memantine-figure7 (Spl Memantine Figure7)

A line graph showing the mean change from baseline in SIB (Severe Impairment Battery) score over 24 weeks of treatment. Two treatment groups are compared: Placebo/Donepezil and Memantine Hydrochloride/Donepezil, with Memantine Hydrochloride/Donepezil showing clinical improvement while Placebo/Donepezil indicates clinical decline over time. Error bars represent standard error of the mean (SEM). The x-axis represents weeks of treatment, and the y-axis shows the mean change in SIB score from baseline, with a reference line marking no change.*

FDA Label Image

Spl-memantine-figure8 (Spl Memantine Figure8)

A cumulative percentage line chart comparing the percentage of patients over 24 weeks completing double-blind treatment with Memantine Hydrochloride/Donepezil versus Placebo/Donepezil, plotted against the SIB (Severe Impairment Battery) change from baseline scores.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.